Replies to post #1168 on Israel-Medical-Healthcare

[ghmm]

Thanks for the replies and info. I saw OPLI is pretty thin (like yesterdays .50 move on little volume) and their balance sheet isn't exactly loaded so not as if their liquidation could be a boon for CanFite.

Your observation at the 12 week mark with the Placebo was pretty insightful. Made me more wonder if the Psoriasis is more clearing up on its own and drug effect is small. They say about 2mg was chosen to go forward an in the one presentation it looks like they tried 1mg and 2mg. Do you know if they had less efficacy at a higher dose? I saw they are trying 4mg in RA so curious about that (Obviously I'd be considered if so).

My thinking was Psoriasis is a pretty big market and given their market cap they'ld only need a small fraction to justify a much higher share price the same for the RA drug.

I don't know about their ED drug it seems not worth the effort (unless someone picks it up) and haven't looked at their Eye Indications (via OPLI).

Its quite interesting given their market cap. I'll probably want to hear a presentation or two before considering a position hopefully they'll present somewhere or do conference calls.